Teva Announces Unique Collaboration with Rimidi to Expand the Reach of its Respiratory Digital Health Platform
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced a new collaboration with Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives.
The collaboration will enable more consumers to have access to Teva’s Digihaler system, a digital health platform designed to enable patients to have more informed treatment discussions with their healthcare providers through personalized care. The collaboration will enable healthcare providers to better integrate patient data into their workflows, supporting proactive remote care across large populations.
The platform can be used to monitor and manage large populations by a network of health systems. It can capture objective and actionable data for asthma patients, thereby creating the mechanism for personalized care.
Integrated with a broad range of medical devices, including cellular and Bluetooth-enabled blood-glucose meters, scales, blood pressure cuffs, pulse-oximeters, insulin dosing pens, and continuous glucose monitors, Rimidi allows for data aggregation across multiple devices into a single, streamlined solution that integrates with the EHR. Digihaler data will be available to providers as part of Rimidi’s new Respiratory Module, which also brings in patient-generated data from an integrated pulse oximeter and relevant data from the Electronic Health Record (EHR) including medical history, diagnoses and laboratory assessments.
“Digital health platforms will succeed only by seamlessly integrating multiple data sources into workflows and systems like electronic medical records (EMR). We believe in building an ecosystem and are delighted to partner with Rimidi as we seek to expand the reach of our platform, and continue to shape digital therapeutics and the integrated care landscape,” said Manny Montalvo, Senior Vice President, Head of Digital Health & Innovation at Teva. “We believe that the future of healthcare is in predictive and preventative care, which is a significant paradigm shift from the standard of care today. That is why we will focus our collaboration and our services on facilitating this change, to help providers deliver better care and help patients manage their condition.”
“With a rich heritage of delivering innovative medicines, alongside technology development capabilities, Teva is uniquely positioned to help the healthcare ecosystem move toward greater integration of objective health data, and create meaningful population-scale solutions to help patients and providers. We envision broad utilization of our platform by consumers, healthcare providers and other technology organizations. In respiratory care, our long-term vision is ambitious and clear: harnessing the power of technology and therapeutics to predict asthma attacks.”
Montalvo continued, “Over the past few years, through a talented and continuously evolving in-house team we have built a robust technology arm within Teva to continue exploring ways to improve patient outcomes. Through our vision for connected therapy, we strive to be at the nexus between patients, healthcare providers, technology, and the future of medicine, exploring new ways for digital health to serve as an economically sustainable solution for small and large healthcare provider organizations, offering timely, data-driven solutions to benefit patients. Our hope is that by working with Rimidi and other capable companies in this space, we will fulfill our mission of improving the lives of patients, and do so by improving the health and effectiveness of our healthcare system – and we’re just getting started.”
“Data from Digital Therapeutics like Teva’s digital inhalers can provide clinicians with a more holistic picture of their patient’s health in between doctor visits,” said Lucienne Ide, Founder and CEO of Rimidi. “To improve patient care and outcomes, the patient-generated health data doesn’t just need to be available to clinicians between visits, but merged with other clinical data and presented within existing EHR workflows and experience.”